Stocks React To February Jobs Report: The Winners And Losers
The markets have offered investors a rollercoaster ride this week, with a flurry of activity and developments that have sent shockwaves through various sectors.
Seres Therapeutics’s Phase 3 Ecospor IV Trial Data SER-109 To Prevent Recurrent C. Difficile Infection Is Published In Jama Network Open
Clinical data show that 91.3% of subjects remained free of C. difficile infection recurrence at 8 weeks, supporting and extending previous Phase 3 study results.
Charter Communications, Braze And Some Other Big Stocks Moving Lower In Today’s Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
iQIYI, Inc. (NASDAQ: IQ) shares dipped 14.1% to $3.31 in pre-market trading after gaining over 9% on Tuesday.
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
Gainers
Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday.
Seres Therapeutics Announces FDA Acceptance Of Biologics License Application For Investigational Microbiome Therapeutic SER-109 For Recurrent C. Difficile Infection For Priority Review
– If approved, SER-109 expected to be the first-ever FDA-approved oral microbiome therapeutic –
– PDUFA target action date is April 26, 2023, with anticipated launch soon thereafter –
–
Important Biotech Catalysts For September 7, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…
Why Seres Therapeutics Shares Are Popping Off Today
Seres Therapeutics Inc (NASDAQ: MCRB) shares are trading higher by 13.24% to $6.12 Wednesday morning after the company announced it completed the rolling submission process for its BLA to the FDA for SER-109 for recurrent C. difficile infection.
Piper Sandler Maintains Overweight on Seres Therapeutics, Raises Price Target to $9
Piper Sandler analyst Edward Tenthoff maintains Seres Therapeutics (NASDAQ:MCRB) with a Overweight and raises the price target from $7 to $9.
